FEIBA®: Mode of action

Haemophilia, Supplement

Volumn 10, Issue 2, 2004, Pages 3-9

  Turecek, Peter L ^a   Varadi K ^a   Gritsch, H ^a   Schwarz, H P ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

Activated prothrombin complex; APCC; Factor VIII; FEIBA ; Inhibitor

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 9; PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VON WILLEBRAND FACTOR; ANTIBODY; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5; PROTHROMBIN COMPLEX CONCENTRATES;

ARTICLE; BLEEDING; BLOOD SAMPLING; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MANUFACTURE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SYNTHESIS; HEMOPHILIA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; DRUG ANTAGONISM; HEMOPHILIA A; IMMUNOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; ANTIBODIES; BLOOD COAGULATION FACTORS; FACTOR V; FACTOR VIII; HEMOPHILIA A; HUMANS; MODELS, BIOLOGICAL;

EID: 11044234839     PISSN: 13550691     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Breen FA Jr, Tullis JL. Prothrombin concentrates in treatment of Christmas disease and allied disorders. JAMA 1969; 208: 1848-52.
2. DeWitt RT, Feinstein DI. Prothrombin complex concentrate. Arch Intern Med 1977; 137: 1211-3.
3. Kelly P, Penner JA. Antihemophilic factor inhibitors. Management with prothrombin complex concentrates. JAMA 1976; 236 2061-4.
4. Kurczynski EM, Penner JA. Activated prothrombin concentrate for patients with factor VIII inhibitors. N Engl J Med 1974; 291 164-7.
5. Sultan Y, Brouet JC, Debre P. Treatment of inhibitors to factor VIII with activated prothrombin concentrate. N Engl J Med 1974; 291: 1087 [Letter].
6. Fekete LF, Holst SL, Peetoom F, De Veber LI. 'Auto' factor IX concentrate: a new therapeutic approach to treatment of hemophilia A patients with inhibitors. International Congress of Hematology, Sao Paulo, 1972; 295 [Abstract].
7. Elsinger F. Shortening of clotting times of hemophilia A plasma with inhibitors induced by activated factor IX concentrates (Fraction FEIBA). ICTH Task Force Meeting Clinical Use of FIX Concentrates, Paris, July 20, 1975 [Oral presentation].
8. Elsinger F. Zum Wirkungsmechanismus von Fraktion FEIBA. In: Landbeck G, Marx R. 6th Symposium on Haemophilia, Hamburg, 1975, Immuno GmbH Heidelberg 1976; 91-4.
9. Prowse CV. Activated prothrombin complex concentrates: approaches to their preparation. Thromb Res 1982; 25: 213-8.
10. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002; 8: 83-90.
11. Barrowcliffe TW, Kemball-Cook G, Gray E. Factor VIII inhibitor bypassing activity. A suggested mechanism of action. Thromb Res 1981; 21: 181-6.
12. Muntean W. Purified complex of factor VIII coagulant moiety and phospholipid: high factor VIII coagulant activity in factor VIII inhibitor plasma. Wien Klin Wochenschr 1984; 96: 829-32.
13. Giles AR, Nesheim ME, Hoogendoorn H, Tracy PB, Mann KG. The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (factor IX) concentrates in rabbits. Blood 1982; 59: 401-7.
14. Lundblad RL, Bergstrom J, De Vreker R et al. Measurement of active coagulation factors in Autoplex-T with colorimetric active site-specific assay technology. Thromb Haemost 1998; 80 811-5.
15. Wilms K, Sander W. Activated prothrombin complex preparations for the treatment of anticoagulant hemophilia. Preparation - method of operation - supply possibility. Folia Haematol Int Mag Klin Morph Blutforsch 1990; 117: 589-93.
16. Sander W, Wilms K. Contribution to the mechanism of the 'factor VIII bypassing activity' (FEIBA) reaction. Folia Haematol Int Mag Klin Morph Blutforsch 1990; 117: 581-7.
17. Turecek PL, Schwarz HP, Barrett N, et al. Partitioning and Inactivation of HIV-1. In: Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White GCII, eds. Advances in Experimental Medicine and Biology - Inhibitors to Coagulation Factors. New York, London: Plenum Press, 1995; 297.
18. Hemker HC, Beguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 1995; 74: 134-8.
19. Váradi K, Negrier C, Berntorp E et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003; 1: 2374-80.
20. Turecek PL, Váradi K, Keil B et al. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation, which can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb 2003; 33: 16-22.
21. Tizzano EF, Soria JM, Coll I et al. The prothrombin 20210A allele influences clinical manifestations of hemophilia A in patients with intron 22 inversion and without inhibitors. Haematologica 2002; 87: 279-85.
22. Nichols WC, Amano K, Cacheris PM et al. Moderation of hemophilia A phenotype by the factor V R506Q mutation. Blood 1996; 88: 1183-7.
23. Nowak-Gottl U, Escuriola C, Kurnik K et al. Haemophilia and thrombophilia. What do we learn about combined inheritance of both genetic variations? Hamostaseologie 2003; 23: 36-40.
24. Turecek PL, Váradi K, Schwarz HP. Prothrombin-factor Xa complex - the active principle behind APCCs. A review and summary of current data. J Thromb Thrombolysis 2004; in press.
25. Mann KG, Nesheim ME, Hibbard LS, Tracy PB. The role of factor V in the assembly of the prothrombinase complex. Ann NY Acad Sci 1981; 370: 378-88.
26. Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988; 53: 505-18.
27. Turecek PL, Váradi K, Gritsch H et al. Factor Xa and prothrombin. Mechanism of action of FEIBA. Vox Sang 1999; 77: 72-9.
28. Himmelspach M, Richter G, Muhr E et al. A fully recombinant partial prothrombin complex effectively bypasses FVIII in vitro and in vivo. Thromb Haemost 2002; 88: 1003-11.
29. Turecek PL, Gritsch H, Richter G, Auer W, Pichler L, Schwarz HP. Assessment of bleeding for the evaluation of therapeutic preparations in small animal models of antibody-induced hemophilia and von Willebrand disease. Thromb Haemost 1997; 77: 591-9.
30. Kristensen AT, Madsen MT, Nielsen GN, Ezban M. Recombinant human FVIIa dose dependently shortens the bleeding time in a rabbit model of antibody induced hemophilia A. Thromb Haemost 1999; 328 (Suppl.): 1038 [Abstract].
31. Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost 2003; 1: 1504-14.
32. Gallistl S, Cvirn G, Leschnik B, Muntean W. Respective roles of factors II, VII, IX, and X in the procoagulant activity of FEIBA. Blood Coagul Fibrinolysis 2002; 13: 653-5.
33. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
34. Billy D, Willems GM, Hemker HC, Lindhout T. Prothrombin contributes to the assembly of the factor Va-factor Xa complex at phosphatidylserine-containing phospholipid membranes. J Biol Chem 1995; 270: 26883-9.
35. Brufatto N, Ward A, Nesheim ME. Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex. J Thromb Haemost 2003; 1: 1258-63.
36. Liu L, Zhang Q, Spencer F et al. Persistent survival of platelet factor Va activity in plasma. Blood 1996; 88 (Suppl. 1): 526a: [Abstract].
37. Baglia FA, Walsh PN. Prothrombin mediates the binding of factor XI to human platelets and its activation by thrombin. Blood 1996; 88 (Suppl. 1): 520a: [Abstract].
38. Baglia FA, Walsh PN. Prothrombin is a cofactor for the binding of factor XI to the platelet surface and for platelet-mediated factor XI activation by thrombin. Biochemistry 1998; 37: 2271-81.
39. Hofmann V, Straub PW. Fibrinopeptide A release by factor-IX concentrates and FEIBA fraction (factor eight inhibitor bypassing activity). Thromb Res 1980; 20: 623-31.
40. London FS, Walsh PN. Zymogen factor IX potentiates factor IXa-catalyzed factor X activation. Biochemistry 2000; 39: 9850-8.
41. Wildgoose P, Kisiel W. Activation of human factor VII by factors IXa and Xa on human bladder carcinoma cells. Blood 1989; 73: 1888-95.
42. Zwaal RF, Comfurius P, Bevers EM. Platelet procoagulant activity and microvesicle formation. Its putative role in hemostasis and thrombosis. Biochim Biophys Acta 1992; 1180: 1-8.
43. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-65.